A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
-
BUSINESS Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
-
REGULATORY Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
-
BUSINESS Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
-
REGULATORY Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
-
BUSINESS Novartis Japan Developing Iptacopan as Priority Product, Initially Targeting 3 Indications
February 4, 2022
-
REGULATORY Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
-
REGULATORY 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
-
BUSINESS 650 Astellas Staffers Choose Voluntary Redundancy, Sales Force Down to 1,200
February 3, 2022
-
REGULATORY DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
-
BUSINESS Sumitomo Dainippon Expects to Get Back on Growth Track in FY2025 after Latuda’s LOE: President
February 2, 2022
-
REGULATORY Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
-
REGULATORY Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
-
ORGANIZATION Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
-
REGULATORY MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
-
BUSINESS Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
-
BUSINESS Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
-
REGULATORY PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
-
BUSINESS Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
-
REGULATORY Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…